These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 21185373

  • 1. The production of 'aerodynamically equivalent' drug and excipient inhalable powders using a novel fractionation technique.
    Taki M, Marriott C, Zeng XM, Martin GP.
    Eur J Pharm Biopharm; 2011 Feb; 77(2):283-96. PubMed ID: 21185373
    [Abstract] [Full Text] [Related]

  • 2. Dry powder formulations for inhalation of fluticasone propionate and salmeterol xinafoate microcrystals.
    Murnane D, Martin GP, Marriott C.
    J Pharm Sci; 2009 Feb; 98(2):503-15. PubMed ID: 18506819
    [Abstract] [Full Text] [Related]

  • 3. Aerodynamic deposition of combination dry powder inhaler formulations in vitro: a comparison of three impactors.
    Taki M, Marriott C, Zeng XM, Martin GP.
    Int J Pharm; 2010 Mar 30; 388(1-2):40-51. PubMed ID: 20026261
    [Abstract] [Full Text] [Related]

  • 4. Combination particles containing salmeterol xinafoate and fluticasone propionate: Formulation and aerodynamic assessment.
    Westmeier R, Steckel H.
    J Pharm Sci; 2008 Jun 30; 97(6):2299-310. PubMed ID: 17879293
    [Abstract] [Full Text] [Related]

  • 5. Agglomerate properties and dispersibility changes of salmeterol xinafoate from powders for inhalation after storage at high relative humidity.
    Das S, Larson I, Young P, Stewart P.
    Eur J Pharm Sci; 2009 Jun 28; 37(3-4):442-50. PubMed ID: 19491036
    [Abstract] [Full Text] [Related]

  • 6. Evidence for the existence of powder sub-populations in micronized materials: aerodynamic size-fractions of aerosolized powders possess distinct physicochemical properties.
    Jaffari S, Forbes B, Collins E, Khoo J, Martin GP, Murnane D.
    Pharm Res; 2014 Dec 28; 31(12):3251-64. PubMed ID: 25015552
    [Abstract] [Full Text] [Related]

  • 7. Effect of milling and sieving on functionality of dry powder inhalation products.
    Steckel H, Markefka P, teWierik H, Kammelar R.
    Int J Pharm; 2006 Feb 17; 309(1-2):51-9. PubMed ID: 16377105
    [Abstract] [Full Text] [Related]

  • 8. Detection and assessment of co-association in inhalable drug particles using aerosol time-of-flight mass spectrometry.
    New A, Prime D, Zomer S, Elder D, Donovan R, Freney E.
    Rapid Commun Mass Spectrom; 2008 Dec 17; 22(23):3873-82. PubMed ID: 19003851
    [Abstract] [Full Text] [Related]

  • 9. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
    Zeng XM, MacRitchie HB, Marriott C, Martin GP.
    Int J Pharm; 2007 Mar 21; 333(1-2):45-55. PubMed ID: 17064863
    [Abstract] [Full Text] [Related]

  • 10. Influence of the polydispersity of the added fine lactose on the dispersion of salmeterol xinafoate from mixtures for inhalation.
    Handoko A, Ian L, Peter SJ.
    Eur J Pharm Sci; 2009 Feb 15; 36(2-3):265-74. PubMed ID: 18996188
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.